Difficult-to-control asthma management through the use of a specific protocol by GIAVINA-BIANCHI, Pedro et al.
REVIEW
Difficult-to-control asthma management through the
use of a specific protocol
Pedro Giavina-Bianchi, Marcelo Vivolo Aun, Carla Bisaccioni, Rosana Agondi, Jorge Kalil
Clinical Immunology and Allergy Department, Faculdade de Medicina, Universidade de Sa˜o Paulo, Sa˜o Paulo, SP, Brazil.
The present study is a critical review of difficult-to-control asthma, highlighting the characteristics and severity of
the disease. It also presents a protocol for the management of patients with this asthma phenotype. The protocol,
which was based on relevant studies in the literature, is described and analyzed.
KEYWORDS: Difficult-to-control; Asthma; difficult-to-treat; Asthma; severe asthma; Resistant asthma; Protocol;
Management.
Giavina-Bianchi P, Aun MV, Bisaccioni C, Agondi R, Kalil J. Difficult-to-control asthma management through the use of a specific protocol. Clinics.
2010;65(9):905-918.
Received for publication on May 11, 2010; First review completed on May 18, 2010; Accepted for publication on June 2, 2010
E-mail: saudesos@terra.com.br
Tel.: 55 11 30713189
INTRODUCTION
The worldwide prevalence of asthma is estimated at 10%,
which makes it a public health problem which has
generated considerable interest among researchers.1-4
In Brazil, the local arm of the International Study of
Asthma and Allergies in Childhood (ISAAC), which
concentrates on children and adolescents, revealed a high
prevalence of asthma symptoms (20-25%) in most Brazilian
cities.5,6 Among prepubescent children, asthma is more
common among boys. However, among adolescents and
adults, women are more often affected and experience
greater asthma severity than those in other groups.7,8
Another major facet indicating the influence of asthma on
morbidity and mortality in Brazil is revealed by data
regarding hospitalizations for asthma via the Brazilian
Public Unified Health Care System, which is responsible
for the treatment of 70-75% of the population. The number
of hospitalizations annually for asthma has been in decline
since 2000, when it peaked at 397,000 (Figure 1).9 Factors
that might have contributed to this decrease in morbidity
include the development and implementation of programs
for the treatment of asthma in Brazil through which asthma
medication is made available to patients at no charge.
However, it is necessary to improve upon the activities
already initiated and make them more homogeneous
throughout the country.
The Hospital das Clı´nicas of the School of Medicine of Sa˜o
Paulo University (HC-FMUSP), located in the city of Sa˜o
Paulo, Brazil, is a tertiary care facility and, therefore,
receives cases that are more complex and severe than those
in other hospitals. It should be kept in mind that difficult-to-
control asthma, although accounting for no more than 5% of
all asthma cases, is responsible for approximately 50% of the
overall costs related to asthma treatment in Brazil. It is also
associated with greater morbidity and mortality, a higher
risk of emergency room treatment being needed, and of
hospitalization, respectively, being 15 and 20 times greater
for such patients than for those with less severe forms of
asthma.10-13
Challenged by the high prevalence of asthma and by high
asthma-related morbidity, which has a strong socioeco-
nomic impact, various health care facilities, medical
societies, and organizations have developed protocols and
consensuses for a more effective approach to asthma and
difficult-to-control asthma.1,12,14-17
In this context, a difficult asthma management protocol
(DAMP) was developed at the Asthma Outpatient Clinic of
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Figure 1 - Hospitalization due to asthma in Brazil as a whole and
in Sa˜o Paulo, Brazil in particular, according to data from the
Information Technology Department of the Brazilian Unified
Health Care System.
IC: inhaled corticosteroid; LABA: long-acting b2 agonist
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the HC-FMUSP Department of Clinical Immunology and
Allergy. The protocol requires the analysis of various
situations which have been grouped into three blocks
(Figure 2). Simultaneously, a line of research dedicated to
this clinical entity was developed, allowing the execution of
various studies that have been published in indexed
journals and presented at national and international
conferences. In addition to the DAMP, the development
and implementation of electronic medical records has
promoted the treatment of, education regarding, and
research into asthma.18
Besides the protocol discussion, the authors reviewed the
literature, mainly the Global Initiative for Asthma (GINA)
guidelines, to classify the recommendations presented here
on the basis of level of evidence (Figure 3).
DISCUSSION
Difficult-to-control Asthma
By consensus, the term ‘‘difficult-to-control asthma’’ is
used in medical literature worldwide. However, various
other terms, such as ‘‘difficult asthma,’’ ‘‘difficult-to-treat
asthma,’’ ‘‘resistant asthma’’ and ‘‘refractory asthma,’’ are
also used. Most patients with difficult-to-control asthma
have severe corticosteroid-dependent asthma or severe
corticosteroid-insensitive asthma.
The 2006 Latin American Consensus on Difficult-to-
Control Asthma defined the disease as an asthma that is
insufficiently controlled despite appropriate therapeutic
strategies adjusted to the degree of clinical severity of the
disease.19,20 Although this definition is subject to a certain
degree of subjectivity, it represents a group of patients who
have specific characteristics and, therefore, should be
approached in a special manner. With the purpose of
making the diagnosis of difficult-to-control asthma more
objective, various consensuses have proposed primary and
secondary criteria. The Latin American Consensus has
defined difficult-to-control asthma as asthma that meets at
least one of the primary criteria and one of the secondary
criteria or both primary criteria (Figure 4).19 In practice, it
can be said that patients have difficult-to-control asthma if
they present asthma that has been treated with systemic
corticosteroids for more than six months or that remains
uncontrolled despite the administration of high doses of an
inhaled corticosteroids (IC) in combination with a long-
acting b2 agonist (LABA).
After the 2006 revision of the Global Initiative for Asthma
(GINA) guidelines, the criteria used to classify asthma
patients as having controlled asthma became stricter:
presenting with nearly asymptomatic disease (no nighttime
symptoms and a maximum of two episodes of daytime
symptoms);presenting with no exacerbations;using rescue
medication twice a week at most;presenting with no
limitations in physical activity;presenting with no adverse
reactions to the drugs used;and presenting with normal
pulmonary function test results.
As of yet, there is no consensus regarding the best manner
to measure asthma control (Figure 5). Some of these
measurements are routinely used during outpatient treat-
ment, whereas others are used specifically in clinical
research. These measurements do not always correlate with
each other, underscoring the need to analyze the results of
various methods of assessment in conjunction with each
other. For instance, forced expiratory volume in one second
(FEV1), one of the indices that is most widely used to
monitor patients, might not correlate with levels of exhaled
nitric oxide or with scores on questionnaires designed to
measure asthma control.21-23 The latter were created for the
purpose of structuring and standardizing the evaluation of
patients, thereby including clinical data and pulmonary
function data, as well as data regarding inflammation
(Figure 6). Some questionnaires have been validated and
are easy to administer, as well as capable of being graded by
scores that allow patient monitoring over a period of time.
Asthma is currently regarded as a syndrome, or at least as
a disease that has various phenotypes.24-26 The two
principal phenotypes, which have clear and distinct
characteristics, are allergic and non-allergic asthma. In
addition to the classification according to etiology, asthma
can be classified according to severity and level of control.
In patients with allergic asthma, the onset of symptoms
tends to be earlier, the disease progresses in a more benign
manner, the rate of hypersensitivity to non-steroidal anti-
inflammatory drugs (NSAIDs) is lower, and the clinical
history (personal and family) usually includes other atopic
diseases (Figure 7). Exacerbations in these patients are
characteristically related to exposure to aeroallergens.
Patients with allergic asthma present with increased serum
levels of total and specific immunoglobulin E (IgE). Specific
IgE can be detected by in vivo tests (immediate skin test:
skin prick test and intradermal test) and by in vitro tests
(enzyme immunoassays). In rare cases, specific IgE is
detected only at the site of the allergic process (local
allergy).27,28
In both phenotypes, there is generally eosinophilic
inflammation of the airways.29 However, neutrophilic
infiltration is more common in non-allergic asthma.
Studies have demonstrated that the number of neutrophils
in induced sputum is significantly greater in patients with
severe asthma than in those with mild asthma or in
individuals without asthma.30 Neutrophilic inflammation
has also been reported in acute exacerbations of the disease
and in sudden-onset fatal asthma.31-33
Figure 2 - Protocol for the treatment of patients with difficult-to-
control asthma.
VCD: vocal cord dysfunction; ABPA: allergic bronchopulmonary
aspergillosis; NSAIDs: nonsteroidal anti-inflammatory drugs; CSS:
Churg-Strauss syndrome
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Respiratory allergy is an example of a type I hypersensi-
tivity reaction in which the allergen is presented to the T
lymphocyte that will mediate a Th2 immune response,
forming IgE antibodies.34-36 It is quite characteristic for a
type I hypersensitivity reaction to occur in two phases: an
immediate phase, occurring as a result of the degranulation
of mast cells and basophils, and a late phase, occurring due
to the recruitment (through chemotaxis) of other cells, such
as eosinophils, which migrate to the site of inflammation.
When the process becomes chronic, these phases over-
lap.37,38 In fact, the immune response is a network, within
which various cells communicate through the secretion of
cytokines and adhesion molecule expression. A recent study
suggested that allergic asthma can be triggered by a Th2
response, even without the presence of IgE.39
In contrast to allergic asthma, the pathophysiology of
which is well-characterized, the etiology of and mechanisms
involved in non-allergic asthma remain unclear. Some of the
possibilities include allergy triggered by unknown antigens
(fungi), persistent infection (caused by Chlamydia trachoma-
tis, Mycoplasma sp. or viruses), and autoimmunity.
A prospective study involving 300 consecutive patients
referred to us with working diagnoses of asthma and
rhinitis revealed that 68.4% of them presented sensitization
to at least one aeroallergen, as demonstrated by skin prick
Figure 3 - Description of levels of evidence (Adapted from GINA).
Figure 4 - Criteria for the diagnosis of difficult-to-control asthma.
SC: systemic corticosteroid; IC: inhaled corticosteroid; LABA:
long-acting b2 agonist; FEV1: forced expiratory volume in one
second; PEF: peak expiratory flow; PFT: pulmonary function test
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tests. The allergens that presented the highest rates of
sensitization were, in decreasing order, dust mite allergens,
cockroach allergens, and cat allergens.40
Difficult-to-control asthma can also be considered a
specific phenotype of asthma, and, as suggested by the
2006 Latin-American Consensus on Difficult-to-Control
Asthma, difficult-to-control asthma can be subdivided into
other phenotypes: labile asthma type I and II, corticosteroid-
resistant asthma, corticosteroid-dependent asthma, and
near-fatal asthma.19,41
Various studies, such as the one by the European
Network For Understanding Mechanisms Of Severe
Asthma (ENFUMOSA study), which was conducted in
2003, have characterized difficult-to-control asthma.8
According to the study, this phenotype was more prevalent
in non-allergic asthma and among females. In adults, the
female/male ratio was 1.6:1 for asthma in general, com-
pared with 4.4:1 for difficult-to-control asthma.
Inflammation with a predominance of neutrophils was also
more common in this phenotype;a prevalence of 36% was
observed, in comparison with a prevalence of 28% in all
asthma cases.
Although there is a consensus that most types of severe
asthma are non-allergic, the Epidemiology and Natural
History of Asthma: Outcomes and Treatment Regimens
study (TENOR study) showed that, in children, IgE levels
are markers of severity.42
We investigated hospital morbidity due to asthma,
analyzing the factors associated with the need for hospita-
lization due to asthma.43 Most of the patients in our study
were female and presented with moderate or severe asthma.
Rhinosinusitis predominated among the associated diseases
and respiratory infections were the principal cause of
hospitalization. Most patients presenting with a history of
smoking had been able to quit the habit. The three principal
factors associated with hospitalization were as follows: poor
treatment adherence, underuse of corticosteroids, and prior
hospitalization.
Various studies have evaluated the relationship between
the severity of asthma and genetic polymorphism:44-51
Figure 5 - Assessment of asthma control.
FEV1: forced expiratory volume in one second; PEF: peak expiratory flow; ACT: asthma control test; ACQ: asthma control questionnaire;
ATAQ: asthma therapy assessment questionnaire; ACSS: asthma control scoring system; AQLQ: asthma quality of life questionnaire
Figure 6 - Questionnaires to measure asthma control.
ACT: asthma control test; ACQ: asthma control questionnaire; ATAQ: asthma therapy assessment questionnaire; ACSS: asthma control
scoring system; FEV1: forced expiratory volume in one second; PEF: peak expiratory flow; and %ES: percentage of eosinophils in
sputum; ND: not determined
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N IL-4 and its receptor.
N Genes related to fibrosis (transforming growth factor-
beta 1 and monocyte chemoattractant protein-1).
N Genes related to pharmacogenetics (aspirin-intolerant
asthma;responses to corticosteroids, b-2 adrenergic
agonists and leukotriene antagonists).
Exposure to tobacco smoke and continuous exposure to
aeroallergens, principally dust mite aeroallergens, fungi
aeroallergens, cockroach aeroallergens, and rat aeroaller-
gens, are also associated with severe asthma (Evidence B).52-
55 The same occurs with infections caused by the respiratory
syncytial virus, Chlamydia trachomatis or Mycoplasma sp.56
The Protocol
The DAMP, developed in the HC-FMUSP Department of
Clinical Immunology and Allergy, is based on three blocks
(sets) of measures (Figure 2).
Block I. In the first block, the measures focus on
analyzing situations that are more commonly associated
with asthma that remain uncontrolled despite the use of
theoretically appropriate treatments. In this block, it is
suggested that the diagnosis of the disease be confirmed
and that environmental controls, treatment adherence, and
medication use be evaluated (Evidence B) and that
treatment be optimized (Evidence A).
Studies have reported that, in most cases, by improving
the evaluation and treatment of these patients, asthma can
be controlled without the continuous use of systemic
corticosteroids or immunosuppressants (Evidence A).19,57
In a study of Leal OM, the potentially aggravating factors of
asthma were, in decreasing order of frequency, as follows:
unsatisfactory knowledge of the disease, incorrect techni-
ques in terms of using medications, gastroesophageal reflux,
inappropriate environmental controls, poor treatment
adherence, rhinosinusitis and polyposis, emotional factors,
allergic bronchopulmonary aspergillosis (ABPA), vocal cord
dysfunction (VCD), failure to use the recommended IC, and
intolerance to NSAIDs.58
The Spanish Consensus on Asthma Management has
divided difficult-to-control asthma into two subgroups: true
difficult-to-control asthma and false difficult-to-control
asthma. False difficult-to-control asthma, perhaps the more
common of the two, is that syndrome in which poor control
is associated with factors that are not intrinsic to the disease
itself, such as incorrect diagnoses of asthma and poor
treatment adherence. This discussion is a more conceptual
one since all patients with clinical profiles consistent with
difficult-to-control asthma should initially be regarded as
having the disease so that the factors that influence disease
control can be properly identified, approached, and mod-
ified.15
According to the DAMP, the diagnosis of asthma should
first be confirmed because asthma may be mistaken for or,
more commonly, accompanied by chronic obstructive
pulmonary disease or congestive heart failure. In some
patients who smoke, it is extremely difficult to distinguish
between pulmonary involvement due to asthma and that
due to chronic obstructive pulmonary disease.
Whether environmental control is being properly per-
formed and whether all allergens and irritants involved
have been identified and avoided should also be investi-
gated. The treatment of respiratory allergies has tradition-
ally been divided into three parts: environmental control,
pharmacological treatment, and immunotherapy. The divi-
sion is purely instructive since these three treatment
modalities complement one another and should be
employed in conjunction with each other.
Although there is a rationale, as well as evidence for the
need to adopt preventive measures to reduce the number of
aeroallergens in the environment (Evidence B), some studies
have been unable to confirm the impact of such measures on
disease control.59,60 The difficulty in confirming the effec-
tiveness of environmental control is due, at least in part, to
Figure 7 - Differences between allergic asthma and non-allergic asthma.
NSAID: nonsteroidal anti-inflammatory drug; IgE: immunoglobulin E
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poor treatment adherence and the complexity of asthma, a
disease that results from the interaction between various
environmental and genetic factors.61 Among the irritants
that are associated with a less favorable evolution of asthma,
smoking and pollution are noteworthy (Evidence B).62-64
In patients with difficult-to-control asthma, the possibility
of occupational asthma should always be considered and
the knowledge that avoidance of identified allergens
improves disease control (Evidence A).65 Specific bronchial
provocation using allergens to confirm the etiology of
asthma is rarely performed in routine clinical practice.
However, it is an important tool for the diagnosis of
inconclusive clinical cases and for the conducting of
research.66,67 Specific bronchial provocation is safe, pro-
vided that it is performed in a standardized manner which
follows protocols.68-73
It is likely that the most common causes of uncontrolled
asthma are poor treatment adherence and insufficient
knowledge on the part of the patient, which results, for
example, in the incorrect use of medication. It is estimated
that asthma treatment adherence ranges from 30 to 50%.74
After a trusting relationship has been established between
the health professional and the patient, the importance of
treatment adherence should be discussed and measures to
ensure that the patient remembers to take the medication
should be proposed (Evidence B). Open dialogue, through
clear and direct questions, is the most appropriate method
for determining whether the proposed treatment regimen is
being followed.75
A series of studies conducted on various continents
revealed that most asthma patients have uncontrolled
asthma, are not aware of that fact, have not been properly
educated, and are not being correctly monitored (Figure 8).
Underuse of ICs, which is observed even among patients
with extremely severe asthma, is among the principal causes
of uncontrolled asthma.76-79 One study demonstrated
eosinophilic inflammatory infiltration throughout the air-
ways of deceased individuals who had presented with fatal
asthma. Many of these individuals were not treating their
asthma regularly and were not using ICs. 80
Although physicians should develop strategies of educa-
tion and guidance (which include giving patients written
treatment plans - Evidence A), some studies have demon-
strated that health professionals are not always trained in
how to do that.81,82 Patients should know that the
respiratory symptoms of asthma result from an inflamma-
tory process in the airways, that there are drugs to treat
exacerbations and others used as maintenance drugs and
that, although asthma is chronic, the disease can be
controlled through treatment, improving quality of life
and reducing morbidity.83 There are various devices for
administering the drugs through inhalation, and the
techniques for using such devices should be taught and
checked at every medical visit as part of the examination.
The use of a peak expiratory flow meter should also be
demonstrated because this will allow home monitoring of
pulmonary function (Evidence B).
Regarding treatment optimization, it is assumed that the
amount of medication prescribed should be the lowest
possible to maintain and control the asthma.
The 2006 update of the GINA guidelines proposed a new
asthma classification based on disease control evaluation:
controlled asthma, partially controlled asthma, and uncon-
trolled asthma. As previously described, the criteria for this
new classification are also rigorous.
The Gaining Optimal Asthma controL (GOAL) study,
conducted in 2004, had a great influence on the changes in
the GINA guidelines.84 It showed that most patients with
asthma do not fully respond to the treatments they were
given. However, treatment response can be achieved
through more rigorous approaches. The GOAL study also
suggested that asthma control can be achieved more rapidly
and in a greater percentage of patients through the use of
ICs in combination with LABAs.
The Salmeterol Multicenter Asthma Research Trial
(SMART) study, conducted in 2006, put in check the
indiscriminate use of LABAs in patients with asthma.85
The SMART was a multicenter, randomized, double-blind,
placebo-controlled study that evaluated 26,355 patients.
There was a small increase in mortality related to the use of
LABAs, principally in African-American patients.
The GINA currently recommends a combination therapy
(ICs and LABAs) for patients with moderate or severe
asthma that has not been controlled by IC use alone. It is
known that, when used continuously, LABAs should
always be prescribed in combination with ICs.86 However,
the question regarding the dose of IC with which LABAs
should first be combined remains unanswered. Is it better
Figure 8 - Rate of severe exacerbations of asthma in the last year.
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for patients to receive high doses of an IC or moderate doses
of an IC in combination with a LABA?
In recent decades, the use of ICs has become the standard
treatment for patients with persistent asthma. The admin-
istration through inhalation has improved disease control,
reducing mortality and, simultaneously, the side effects
triggered by the use of systemic steroids (Evidence A).87
However, certain local effects, such as oropharyngeal
candidiasis and dysphonia, can occur and can lead patients
to discontinue treatment.88 With the increase in the use and
doses of ICs, studies have also reported esophageal candi-
diasis as being a complication of asthma treatment.89-91
Esophageal candidiasis is underdiagnosed and often oligo-
symptomatic. The diagnosis is made only when there is a
high degree of suspicion, principally in patients using high
doses of ICs.
It has been demonstrated that only by changing ICs and
inhalers can this complication be avoided and treated.92
Another interesting observation is that, just as oral asepsis
after IC use prevents oral moniliasis, the ingestion of fluids
and solids may prevent and treat esophageal infection.93
This effectively constitutes esophageal lavage and removes
the medication deposited in the mucosa.
The treatment of asthma should always be adjusted so
that the morbidity and mortality from the disease are as low
as possible, providing patients with a better quality of life.
Complete control should always be the goal. However,
when this goal cannot be achieved, the objective of the
treatment should be to attain the best response and the
fewest adverse reactions. Once asthma is properly con-
trolled by a treatment regimen, the medication dose should
be progressively reduced to the minimum required to
maintain disease control.
Block II. In the second block of the DAMP, co-morbidities
and associated diseases should be investigated and identified
because the treatment of these diseases aids in controlling
asthma.
We have recently analyzed the data obtained from the
electronic medical records of 245 patients treated for severe
asthma.94 Rhinitis, gastroesophageal reflux disease (GERD),
and bronchiectasis were the most common co-morbidities
observed, showing a high prevalence. Therefore, in patients
with severe asthma, associated diseases should be investi-
gated as the cause of respiratory symptoms and uncon-
trolled asthma. Some of the principal entities that aggravate
the progression of asthma are described and discussed
below.
Rhinosinusitis. Rhinitis is an inflammatory disease of
the nasal mucosa that is clinically characterized by four
principal symptoms: rhinorrhea, sequential sneezing,
pruritus, and nasal congestion.95,96 In the case of allergic
rhinitis, the inflammatory process is induced by an IgE-
mediated immune response.
Rhinitis-related morbidity is high and represents a
heavy socioeconomic burden due to direct and indirect
costs.95-101 The estimated prevalence of allergic rhinitis in
the general population is 30%, and allergic rhinitis is the
most common chronic disease in children, which makes it a
serious public health problem.95,96,102,103
The ARIA consensus was published in 2001.96 In addition
to some new conceptual modifications regarding rhinitis,
such as a change in the classification of the disease, the
ARIA highlighted the importance of being aware of the
influence that the upper airways exert on the lower airways
and vice-versa (Figure 9).96,104
Allergic rhinitis and allergic asthma are currently recog-
nized as manifestations of a single entity, ‘‘chronic allergic
respiratory disease,’’ also known as ‘‘united airway dis-
ease.’’ There is epidemiological, pathophysiological, and
clinical evidence to support an integrated view of these
diseases, allowing a better understanding of their interac-
tions (Figure 10).96,97,105-108 The great majority of patients
with asthma have rhinitis, the latter being a risk factor for
the development of the former.
Some studies have demonstrated that the presence of
severe rhinitis in patients with asthma is associated with
less favorable evolution. It has also been shown that the
treatment of nasal symptoms can be beneficial to the lower
airways (Evidence A), reducing the number of emergency
room visits and hospitalizations, as well as the severity of
bronchial hyperreactivity.106,109-112
These studies and others with similar results do not
suggest that patients with rhinitis and asthma should be
treated with nasal medications alone;what they do recom-
mend is that the teachings of the ARIA initiative should not
be forgotten.
Figure 9 - Objectives of the Allergic Rhinitis and its Impact on Asthma initiative.
Figure 10 - Pathophysiological evidence for the interaction
between allergic rhinitis and allergic asthma.
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Gastroesophageal Reflux Disease (GERD). Patients with
GERD can present with respiratory manifestations. The
prevalence of GERD is higher in patients with asthma than
in the general population, and GERD is associated with
difficult-to-control asthma. However, there is no definitive
scientific evidence that the treatment of one of the two
diseases translates to a more favorable progression of the
other (Evidence C).
Asthma and GERD frequently coexist.113 Concomitance
between symptoms of dyspnea and reflux is quite common,
and large-scale studies have shown that the degree of reflux
can be as much as 60% greater in individuals with asthma
than in those without.114 In a study conducted in the United
Kingdom, the prevalence of GERD symptoms among
patients with difficult-to-control asthma was found to be
75%.115
It has been shown that GERD exacerbates asthma through
mechanisms involving vagus nerve stimulation (esophago-
bronchial reflex) or microaspiration of gastric contents into
the airways.
Adverse Drug Reactions. Aspirin-induced asthma is a
clinical entity characterized by asthma and intolerance to
aspirin or NSAIDs.116 Aspirin-induced asthma and nasal
polyposis (Samter triad) are associated with an increase in
asthma severity.117,118
Although hypersensitivity to NSAIDs and aspirin affects
only 0.6-2.5% of the general population of adults, it occurs in
5-20% of adults with asthma.119 It has previously been
demonstrated that many patients are not able to perceive
this exacerbation. In a study conducted in Europe and invol-
ving 500 patients diagnosed with aspirin-intolerant asthma,
90 (18%) were unable to perceive any worsening of the
symptoms prior to the provocation test.120
Vocal Cord Dysfunction (VCD). The features of VCD
include episodes of involuntary paradoxical movements
caused by vocal cord adduction during respiration and
resulting in airway obstruction. The clinical profile is
characterized by stridor, dyspnea, and wheezing, princi-
pally in the cervical region. Although VCD generally is seen
in patients with asthma, it can also occur in an isolated form
in individuals without respiratory disease.
The prevalence of VCD, which is higher in patients with
difficult-to-control asthma, has yet to be well established.121
In Brazil, the prevalence of VCD in patients with severe
asthma and difficult-to-control asthma were found to be
17.5% and 19.5%, respectively.122 However, VCD is com-
monly underdiagnosed, which is responsible for the low
reported prevalence of this disease at various health care
facilities.
The pathophysiology of VCD is unknown, and no organic
cause has yet been found. The most accepted hypothesis is
that its etiology is psychogenetic and that attacks of VCD are
commonly triggered by psychological factors.123-126
Two factors make VCD more intriguing and more
difficult to diagnose than other similar diseases. First, there
is a confounding overlap between asthma and VCD attacks
when they coexist.121,124 Second, VCD appears as attacks,
and certain patients, especially those with VCD in isolation,
can be asymptomatic between attacks. Since there are no
diagnostic criteria for VCD, clinical suspicion is based on
discrepancies between the clinical profile, the complemen-
tary test results, and the therapeutic response.
A definitive diagnosis of VCD can be obtained by means
of laryngoscopy. When performed during an attack, it
shows a typical pattern, which consists of the adduction of
the anterior two thirds of the vocal cords during inspiration,
forming a posterior cleft with a ‘‘diamond shape.’’121,124
Many patients with VCD are misdiagnosed as having
severe asthma or difficult-to-control asthma and, therefore,
receive inadequate or inappropriate treatment since VCD
treatment is based on psychotherapy and speech therapy
(Evidence C). It should be noted that these patients receive
the same treatment as do those with difficult-to-control
asthma, including the continuous use of systemic corticos-
teroids. In addition to producing a limited clinical response,
this treatment regimen has undesirable side effects
(Evidence B). However, since most patients with VCD also
suffer from asthma, the latter should not be ignored.
Recently, a specific questionnaire designed to raise
awareness of the possibility of VCD was developed in
order to identify patients who are more likely to be
diagnosed with the disease (Figure 11).122 In essence, the
questionnaire attempts to identify whether there are
discrepancies or inconsistencies between the clinical profile,
the complementary tests, and the treatment of the patient.
Allergic Bronchopulmonary Aspergillosis (ABPA). The
complex disease ABPA is triggered by a hypersensitivity
reaction to allergens of the fungus Aspergillus fumigatus. The
prevalence of ABPA among asthma patients sensitized to A.
fumigatus in Brazil has been reported to be 20%.127
The course of ABPA includes periods of exacerbation
and remission. The disease can progress to a phase in which
the patient presents with central bronchiectasis and pul-
monary fibrosis, resulting in chronic respiratory failure.128
Since ABPA is accompanied by cystic fibrosis or asthma
(especially difficult-to-control asthma), it is another disease
in which the diagnosis is complicated. The challenge is to
diagnose ABPA in its initial stages, when only the
serological markers are present and the processes of
cicatrization/fibrosis are not yet evident (ABPA with central
bronchiectasis). Unfortunately, ABPA is often diagnosed
only after years of monitoring, making it difficult to prevent
irreversible lung damage.128-131
Some ABPA markers are difficult to detect (especially at
the early stages of the disease) and, in general, the markers
do not present simultaneously during a single evaluation.
At least three factors make it difficult to diagnose the
disease:
1) ABPA manifests as attacks.
2) The treatment of ABPA, which consists principally of
using systemic corticosteroids, hinders with the diag-
nostic investigation.
3) The current methods for detecting specific antibodies
(IgE and IgG) are not accurate or easily reproduced.
Some studies, especially those involving patients with
cystic fibrosis, have reported that, based on the humoral
response to recombinant allergens, it is possible to distin-
guish between ABPA patients and asthma patients sensi-
tized to A. fumigatus, but without ABPA.132,133 Other
studies, however, have reported that determination of the
serum levels of IgE against recombinant allergens of A.
fumigatus does not aid in diagnosing ABPA or in confirming
sensitization to the fungus.134,135
It has been reported that there is a discrepancy between
the intradermal test results and the serology results in
patients suspected of having ABPA. Intradermal tests seem
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to be more sensitive, with late reactions having been
reported.136
In this context, the diagnosis of ABPA remains complex
and challenging.
Immunodeficiencies. Immunodeficiencies with recurrent
respiratory infections are included in the differential
diagnosis of asthma. However, when the two diseases are
present in the same patient, the infections make asthma
control difficult and they may trigger asthma exacerbations.
Secondary immunodeficiencies are more common than
are primary immunodeficiencies and, in patients with
asthma, the most prevalent type of immunodeficiency is
that which results from corticosteroid therapy.137
Among the primary immunodeficiencies, the most pre-
valent are selective IgA immunodeficiency and common
variable immunodeficiency (CVID), both of which are
responsible for pulmonary infections and respiratory mani-
festations.138,139 The prevalence of respiratory impairment
is high, and 25% to 50% of the patients present with
bronchiectasis, obstructive pulmonary diseases, or restric-
tive pulmonary diseases.140,141 Recurrent infections are
the principal cause of pulmonary involvement. However,
a chronic inflammatory process, the etiopathogenesis of
which remains unclear, is also observed in the lungs of these
individuals.142,143 These data warrant intensive monitoring
of the respiratory system of CVID patients and justify their
treatment with gamma-globulin therapy, which has chan-
ged the prognosis of the disease (Evidence A).142,143
Many patients with CVID remain symptomatic, with
respiratory complaints. These symptoms can mimic and be
mistaken for those of asthma, and it is extremely difficult to
confirm the diagnosis of asthma, as well as to determine the
allergic etiology of asthma in patients with CVID.
We showed that in CVID patients, in addition to
pulmonary function testing, bronchial provocations can
aid in the diagnosis of asthma and can help to confirm the
allergic etiology of the disease since the vast majority of
patients present specific serum IgE that cannot be detected
by skin tests or by in vitro tests.39
Although patients with CVID synthesize low quantities of
antibodies, perhaps the production of IgE in the airways can
be enough to trigger allergic asthma. Another hypothesis
has to be considered: the existence of a Th2 immune
response with participation and activation of T lympho-
cytes, mast cells and eosinophils, without the presence of
the IgE antibody.
Churg-Strauss Syndrome. Churg-Strauss syndrome (CSS)
is a necrotizing systemic vasculitis of medium and small
blood vessels characterized by asthma, eosinophilia, and
eosinophilic or granulomatous tissue inflammation. It is
currently recognized as one of the antineutrophil cytoplasmic
antibody (ANCA)-associated vasculitides which is present in
half of all CSS patients.144-146
Asthma and upper respiratory symptoms are present in
nearly all CSS patients, besides the presence of other
manifestations of systemic vasculitis. The syndrome man-
ifests in three consecutive phases: a prodromal phase
consisting of respiratory manifestations (rhinosinusitis and
asthma), a second phase consisting of peripheral blood
eosinophilia and eosinophilic tissue infiltrates, and a third
phase consisting of systemic vasculitic manifestations.147-150
Corticosteroids are the cornerstone of CSS therapy and
provide control of disease activity in the great majority of
cases (Evidence A). However, 25-50% of CSS patients
relapse within two years of achieving remission and a
substantial proportion of patients present adverse drug
reactions with significant morbidity.147-149,152 Asthma is not
considered in the definition of CSS remission, and most
patients continue to present with asthma and upper
respiratory symptoms, requiring ongoing treatment.
We reported the first case of a patient with CSS who
received anti-IgE antibodies for the treatment of difficult-to-
control asthma.153,154 In parallel with the description of our
clinical case, there were case reports of patients who
developed CSS during anti-IgE antibody use.155-157 These
studies have sparked a discussion as to whether omalizu-
mab can trigger CSS, a discussion that is similar to that
regarding anti-leukotrienes. After the analysis of the cases, it
Figure 11 - Specific questionnaire for the clinical suspicion of vocal cord dysfunction.
Q: question;FEV1: forced expiratory volume in one second; and PEF: peak expiratory flow
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is argued that the patients probably had CSS before the use
of the anti-IgE antibody and that the disease was masked by
the use of systemic corticosteroids. The use of the anti-IgE
antibody allowed the discontinuation of the systemic
corticosteroids, increasing the activity of CSS and allowing
the diagnosis to be made.158-162
Discontinuation of the use of systemic corticosteroids in
patients with asthma, especially in those with severe asthma
who are suspected of having CSS, should be undertaken
with care.
Block III. After the situations and co-morbidities des-
cribed in Blocks I and II have been identified and controlled,
additional measures might be necessary.
Due to the specialization and deepening of knowledge in the
health area, diseases that are more severe and complex might
be approached more effectively if multiprofessional and
multidisciplinary teams were to be involved. Some studies
have demonstrated the benefits of physical therapy and
physical exercise to treat asthma (Evidence C).163-165 Psycho-
logical evaluation can also be beneficial, principally in
prolonged and severe cases (Evidence C). It has been shown
that the prevalence of symptoms of anxiety and depression is
higher in patients with asthma than in patients with chronic
obstructive pulmonary disease.166
In a minority of patients, prolonged, continuous use of
systemic corticosteroids, often at high doses, is required.
When the use of systemic corticosteroids is discontinued,
asthma control worsens. In patients with this type of asthma,
which is designated corticosteroid-dependent asthma, the
adverse effects of the treatment become a serious problem
(Evidence A).
A small portion of patients do not respond adequately to
glucocorticoids, regardless of the dosage. These patients are
designated corticosteroid-insensitive or corticosteroid-resis-
tant, and they also present with severe side effects.167 The
lack of response to the medication might be only partial and
might occasionally be reversed by treating the inflammatory
process. Clinically, patients with corticosteroid-insensitive
asthma are those who present with an FEV1 , 70% of the
predicted value and who do not show a 15% and a 200 ml
improvement in FEV1 after treatment with prednisolone
40 mg (or equivalent), for 14 days. If there is no treatment
response, the dose can be doubled for an additional 14
days.168
In cases in which insensitivity to corticosteroids is due to
a reduction in the affinity between the drug and its receptor
at least two mechanisms have been described.169,170 There
can be genetic (inherited) modifications in the receptors or,
more commonly, the inflammatory process induces a
reduction in affinity.
Neutrophilic asthma is another phenotype of the disease
that might not respond adequately to glucocorticoids.171-173
These drugs antagonistically induce and inhibit the apop-
tosis of eosinophils and neutrophils, respectively. There is
controversy in the literature as to whether the neutrophilic
infiltrate is the cause of airway inflammation or a conse-
quence of the chronic use of corticosteroids. There is
evidence that, in the bronchial mucosa of patients with
difficult-to-control asthma, eosinophils predominate in
some cases and neutrophils predominate in others
(Evidence B). There are also two subgroups of fatal asthma:
sudden-onset fatal asthma, which is accompanied by
neutrophilic inflammation, and slow-onset fatal asthma,
which is accompanied by eosinophilic infiltrate.32
Various drugs that somehow modulate inflammation
have been used as alternative treatments in corticosteroid-
insensitive and corticosteroid-dependent patients (Evidence
C). Such drugs include colchicines, chloroquine, dapsone,
macrolides, immunoglobulins, gold salts, azathioprine, cyclo-
sporine, and methotrexate.19 Although some of these agents
might be useful in treating certain patients, they do not have
consistent effects and some of them have been associated with
severe adverse reactions. In the absence of studies determi-
ning the subgroups of patients that would benefit the most
from using these drugs, they should be prescribed on a case-
by-case basis.
Omalizumab is a humanized anti-IgE monoclonal anti-
body that has recently been made available in Brazil for the
treatment of difficult-to-control allergic asthma. The clinical
effectiveness of omalizumab has been proven in various
studies, principally with regard to the following parameters:
exacerbations, quality of life, use of rescue medication, and
reduction in the use of ICs (Evidence B).[174-176] The
principal challenges facing the use of omalizumab are the
correct characterization of the profile of patients who would
benefit the most from anti-IgE antibody use and the limited
access to the medication, which is principally due to its high
cost.
CONCLUSIONS
Asthma is a chronic disease of high prevalence and a
public health problem. It affects individuals of all ages and,
if left uncontrolled, it causes limitations of activities of daily
living and can lead to death.
The treatment of asthma, principally that of the allergic
phenotype, has greatly evolved, and the vast majority of
patients can present with controlled asthma, no symptoms,
and normal pulmonary function. However, a small but
significant portion of individuals with asthma present with
difficult-to-control asthma, which is associated with high
morbidity and cost.
The development of protocols for the treatment of
difficult-to-control asthma, such as that which is presented
in the present study, have allowed patients with this disease
to be managed more effectively, possibly reducing morbid-
ity and mortality and improving their quality of life. The
objective of the protocols is to guide physicians; they do not
exclude the idea of personalized medicine.
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